Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

Condition:   Asthma
Interventions:   Drug: Mepolizumab 100mg SC;   Drug: Albuterol/salbutamol MDIs;   Drug: Omalizumab
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified January 2016

View full post on ClinicalTrials.gov: asthma | received in the last 14 days